SY-5609 + gemcitabine

SY-5609 + gemcitabine is an investigational combination therapy being evaluated for the treatment of advanced solid tumors, particularly relapsed metastatic pancreatic cancer. SY-5609 is an oral, selective, noncovalent, and reversible small molecule inhibitor of cyclin-dependent kinase 7 (CDK7), which plays a critical role in transcriptional regulation and cell cycle progression. Gemcitabine is a well-established nucleoside analog chemotherapy agent that inhibits DNA synthesis. The combination leverages the transcription and cell cycle inhibition of SY-5609 with the cytotoxic activity of gemcitabine. Preclinical and early clinical data support the rationale for this combination, which is being tested in ongoing phase 1 trials for efficacy and safety in patients with advanced solid tumors, including pancreatic cancer.